A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine

• Status: Recruiting
• Trial end date: 2022-12-09
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to evaluate the effect of erenumab on medication-specific treatment satisfaction.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Amgen
• Treatments: Erenumab

Criteria

Inclusion Criteria:

• Age ≥ 18 years

• Participant has provided informed consent

• History of migraine (with or without aura) for ≥ 12 months before screening

• ≥ 4 migraine days per month on average across the 3 months prior to screening

• Treatment with 1 oral migraine preventive medication

• Participant reports to their provider intolerance or insufficient response with their current preventative treatment

Exclusion Criteria:

• History of cluster headache or hemiplegic migraine headache

• Unable to differentiate migraine from other headaches

• Evidence of substance-related disorders

• Active chronic pain syndromes (eg, fibromyalgia and chronic pelvic pain)

• No therapeutic response with > 3 migraine preventive medication categories

• Used a prohibited medication, device, or procedure

• Other clinically significant disorder, condition, or disease